Essayer OR - Gratuit

Resisting & Adapting to Infectious Diseases to Prevent Future Pandemics

BioSpectrum Asia

|

BioSpectrum Asia Sep 2021

Understanding the science behind infectious disease R&D, and what interventions are being implemented to potentially prevent future pandemics caused by emerging infectious diseases such as COVID-19

Resisting & Adapting to Infectious Diseases to Prevent Future Pandemics

Stephan Baumann, Infectious Disease Segment Manager, Agilent Technologies, USA

For over a year the world has been battling the newly emerged infectious disease: the SARS-CoV-2 virus that caused the COVID-19 disease. With over 4.1 million deaths globally (as of July 27, 2021), the COVID-19 pandemic wreaked havoc within communities and triggered significant disruptions to the way we live, work, and socialise.

Across the Asia Pacific region, many countries continue to resist the impact of the pandemic and look to protect their citizens. India now has the second highest number of COVID-19 cases in the world - reporting over 400,000 daily cases at its peak for several days in May 2021. Several other countries in the region have seen the reemergence of COVID-19 clusters, with particular concern around newly emerging COVID-19 variants across the world. Singapore also recently saw the emergence of new clusters and subsequent increase in cases, prompting the government to reimpose stricter guidelines on social gatherings to help prevent further spread of transmission.

As the world continues resisting and adapting to the COVID-19 pandemic, academics and research scientists are looking to provide solutions to some of the unanswered questions about the causal SARS- CoV-2 virus. There are multiple research areas to investigate: the genetic make-up of the virus, its molecular structure, and the development of targeted therapeutics and preventative medicines – e.g., vaccines – to help eradicate the virus. In particular, one key focus within the research community has been the so-called “spike protein”.

Understanding the spike protein

PLUS D'HISTOIRES DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits

US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation

US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio

Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema

A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing

Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

IIT-D and AIIMS develop swallowable microdevice for microbiome study

Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

Translate

Share

-
+

Change font size